Contract Notice Detail
Summary Information
Summary Information
Request Reference:
51036924 _ AQ 2022/173
Request Name:
51036924 _ AQ 2022/173 Paliperidona 50 mg susp inj LP
Phase:
Tendering Phase
State:
Awarded
Description:
51036924 _ AQ 2022/173 Paliperidona 50 mg susp inj LP
Procedure Type:
VortalGOV - Acquisition under a Framework Agreement (via Direct Award)
Lot Name
Lot Base Price
Expected Duration
P1066 - PALIPERIDONA [50 MG; SUSP INJ LP; SERINGA]
-
30
(
Days
)
Object of the Contract
Object of the Contract
Type of Contract:
Supplies Acquisition
Main Object CPV Main Category:
Rua José António Serrano PORTUGAL
CPV Main Vocabulary
33600000-6 - Pharmaceutical products
CPV Supplementary Vocabulary
Additional Classifications List
Scheduling
Scheduling
Request online publishing date:
7/11/2024 5:07 PM
(UTC +1 hour)
National official publishing date and time (DR):
11/7/2022 5:00 PM
(UTC 0 hours)
Due datetime for receiving replies:
7/15/2024 10:00 AM
(UTC +1 hour)
Financial Settings
Financial Settings
Define Warranties?
No
Contract Documents
Contract Documents
Document Name
Description
Doc Classification
Modelo Declaração _ ANEXO I.doc
Modelo Declaração _ ANEXO I.doc
Download
51036924 Lista Artigos.pdf
51036924 Lista Artigos.pdf
Download
51036924 Convite_signed.pdf
51036924 Convite_signed.pdf
Download
Object of contract
This contract is subject to renewal?
No
The procurement is related to a project and/or programme financed by European Union funds?
No
Legal, economic, financial and technical information
The contract is reserved to sheltered workshops and economic operators aiming at the social and professional integration of disabled or disadvantaged persons?
No
Questionnaire
Questionnaire
1
Lot Title
P1066 - PALIPERIDONA [50 MG; SUSP INJ LP; SERINGA]
1.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
P1066
PALIPERIDONA [50 MG; SUSP INJ LP; SERINGA]
50,000000
NXTWY.UMT.17650
Buyer Comment:
500189412 | Janssen - Cilag Farmacêutica, Lda. | CPA:2022173/74/0204 | NºAIM:5372123; 502836148 | FARMALTER-PRODUTOS FARMACEUTICOS E DIETETICOS, LDA | CPA:2022173/2317/0103 | NºAIM:5827001; 506303004 | Alter Genéricos - Comercialização de Produtos Genéricos, Lda. | CPA:2022173/2318/0107 | NºAIM:5826862;
TOTAL
(The amounts shown do not include VAT)
Evaluation
Evaluation
Vision
Avaliação
Definir modelo de avaliação
Sim
Não
Modalidade de avaliação
Selecione…
Monofator
Método de Avaliação
Selecione…
Manual
Divulgar critérios de avaliação
Sim
Não
Critérios da Avaliação
1 - P1066 - PALIPERIDONA [50 MG; SUSP INJ LP; SERINGA]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
Preço
100%
Normas de desempate
Definir normas de desempate?
Sim
Não
Normas de desempate
Nível
Tipo de Norma
Descrição
Critério
1
Sorteio
De acordo com o ponto 7. do convite
-
Public Messages
Public Messages
Type
Reference
Subject
Date
No items found...